Moleculin Biotech, Inc. (MBRX) NASDAQ
2.46
-0.18(-6.82%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.46
-0.18(-6.82%)
Currency In USD
Address
5300 Memorial Drive
Houston, TX 77007
United States of America (the)
Phone
713 300 5160
Website
Sector
Healthcare
Industry
Biotechnology
Employees
17
First IPO Date
June 02, 2016
| Name | Title | Pay | Year Born |
| Walter V. Klemp | Co-Founder, Chairman, President & Chief Executive Officer | 1.02M | 1960 |
| Donald H. Picker | Chief Scientific Officer | 544,691 | 1946 |
| Jonathan Foster | Executive Vice President & Chief Financial Officer | 672,405 | 1964 |
| John Paul Waymack | Senior Chief Medical Officer | 0 | 1952 |
| Waldemar Priebe | Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board | 0 | N/A |
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.